Stock Down Under

Money-Making Insights On

ASX-Listed Stocks

Find Us in

Stocks Down Under Analysts delve into a large variety of ASX-listed stocks and sectors.

Help: I own a delisted ASX company! What can I do?

By Nick Sundich | June 21, 2024

If you own shares in a delisted ASX company, you’re probably wondering what to do. Some stocks have a happy ending in being taken over at a healthy premium, but some end up going bankrupt and leaving shareholders having lost all their money. But it may not be the end of everything for investors even…

Read More

Where to Next for Bitcoin? Here’s where the world’s most famous cryptocurrency might be headed in the next 12 months

By Ujjwal Maheshwari | June 21, 2024

Where to Next for Bitcoin? To say Bitcoin (BTC) has been on an interesting journey over the past few months in an understatement. After a period of consolidation that lasted around three months, the market is buzzing with speculation about its next move. Adding to the excitement is the launch of Australia’s first spot bitcoin…

Read More

The Guzman y Gomez ASX IPO gained over 35% on its first trading day – but will the hot run last?

By Nick Sundich | June 20, 2024

The Guzman y Gomez ASX IPO was a spectacular success. After months of rumours, and a few weeks marketing (and criticism), the company debuted on June 20, 2024 and debuted at $30 – well up from the $22 it raised capital at.     Guzman y Gomez began in October 2006, opening its first store…

Read More

Share buybacks: Are they a good sign or a waste of money?

By Nick Sundich | June 20, 2024

Share buybacks are a controversial topic amongst investors. Some say it is a waste of money, others will welcome it (just because they have their own shares bought back). We thought we’d recap what share buybacks are, some of the advantages or disadvantages and whether or not they are ultimately a good or bad thing.…

Read More

AFT Pharmaceuticals (ASX:AFP): A gem of a dual-listed healthcare company

By Nick Sundich | June 20, 2024

AFT Pharmaceuticals (ASX:AFP) may not spring to mind as the best company to have come out of New Zealand. Many investors would say that title belongs to Xero (ASX:XRO). Nonetheless, however much AFT Pharmaceuticals has slipped under the radar, it deserves a lot more attention than it has received from investors, given its progress since…

Read More

Can Tabcorp’s nеw boss improve the stock’s dwindling odds?

By Nick Sundich | June 19, 2024

Tabcorp (ASX: TAH) has had a dog of a year, with its share price dropping roughly 40% in the last 12 months. It has been a difficult decade, to say the least. The company has faced intense competition from online players, has fought off takeover attempts, merged with Tatts Group then demerged its lotteries business.…

Read More

The dream of Bitcoin ETFs on the ASX will soon become a reality, but here’s what investors need to know

By Nick Sundich | June 19, 2024

For a long time, the concept of bitcoin ETFs has been little more than a pipedream, until the SEC finally gave the concept regulatory approval. Cryptocurrencies have seen a surge in popularity over the past decade, with Bitcoin being the most well-known and dominant player in the market – it is just over half of…

Read More

Should I buy Apple shares from Australia? Can the US$3.3tn behemoth grow any further?

By Nick Sundich | June 18, 2024

Investors asking themselves, ‘Should I buy Apple shares from Australia,’ are not just considering buying shares any company, but the world’s largest. Capped at over $3tn, the Silicon Valley-based tech (and arguably luxury) company has risen to spectacular new heights since the departure and death of Steve Jobs, surpassing $1tn in August 2018, $2tn in…

Read More

The ASX CHESS Replacement: Will the excruciating wait finally be over by the end of the 2020s?

By Nick Sundich | June 18, 2024

The long-promised ASX CHESS replacement has been a saga that likely has more twists and turns to come. Despite prior hopes we could’ve had it in April 2023, it may not be until the end of this decade. So, why have things gone so wrong, will we ever see it and where are things at…

Read More

AI Wars: Which Tech Giant’s Artificial Intelligence is better?

By Ujjwal Maheshwari | June 17, 2024

Artificial Intelligence (AI) is no longer just a futuristic concept—it’s here, transforming our daily lives from the way we commute with self-driving cars to how we interact with our smart devices at home. As AI continues to evolve, an important question surfaces: Who is really pushing the boundaries of this technology?   Why It Matters…

Read More

Sector Analysis

The-Best-Mining-Stocks

The Best Mining Stocks

Mining and resources stocks have substantial potential given demand for all types of resources and metals from gold and iron ore to battery metals like lithium and graphite! There are over 700 stocks in this sector from big miners to small cap explorers.

The-Best-Tech-Stocks

The Best Tech Stocks

Tech stocks are appetising in the context of an increasingly digital world ranging from data centre builders, cloud services providers and cybersecurity companies. Many of the ASX's best performing stocks in the last decade have been tech stocks.

The-Best-Uranium-Stocks

The Best Uranium Stocks

Uranium stocks are in a good spot right now with rising demand for clean energy, nuclear energy making a comeback and yellowcake pricing reaching levels not seen since the GFC. This has enabled many companies with mothballed projects to bring them out of hibernation.

Untitled design

The Best Healthcare Stocks

There are dozens of Healthcare stocks on the ASX ranging from big names like CSL and Cochlear with established products and markets, to small cap biotechs and medtechs hoping to follow in their footsteps and commercialise the next big innovation.

The-Best-Mining-Stocks

The Best Mining Stocks

The-Best-Tech-Stocks

The Best Tech Stocks

The-Best-Uranium-Stocks

The Best Uranium Stocks

Share Type Analysis

The Best ASX Stocks Right Now

The Best ASX Stocks Right Now

The quest for the best stocks to buy now is a never-ending one, but armed with a solid investment strategy, you can create a diversified portfolio that stands the test of time. We provide our Top 10 ASX stocks we think investors should consider right now. 

The Best ASX Stocks Right Now

The Best ASX Stocks Right Now

The Top Penny Stocks

The Top Penny Stocks

Navigating ASX Penny stocks, can be complex, given the diversity of companies operating in various sectors and the high risk associated with them. But there is potential for impressive returns if investors can find the right company.

The Top Penny Stocks

The Top Penny Stocks

The Top Dividend Stocks

The Top Dividend Stocks

Investing in Dividend stocks can provide an additional source of income, and so are popular with a wide variety of investors. But only some companies pay dividends, and even consistent payers can fluctuate payouts year to year. We outline the Top Dividend Stocks for investors to consider.

The Top Dividend Stocks

The Top Dividend Stocks

size set 1

Top ASX Index Funds

Explore our comprehensive analysis of the top ASX index funds, carefully curated by industry experts. Discover which funds are currently outperforming and why, based on detailed market trends and performance metrics. Ideal for both new and seasoned investors seeking strategic investment opportunities on the ASX. Dive into our report today to make informed investment decisions.

size set 1

Top ASX Index Funds

size 2

The Top Blue Chip Stocks

Discover the best ASX blue chip stocks for investment. Our industry experts provide in-depth analysis on these well-established companies with strong credit ratings and a long history of performance and stability. Explore market leaders like Commonwealth Bank of Australia, BHP Group Ltd, and National Australia Bank Limited.

size 2

The Top Blue Chip Stocks

size 3

Top ASX Growth Stocks for Investing

Explore our comprehensive analysis of the top ASX growth stocks for investing. Our industry experts have curated a detailed report on the most promising opportunities available in the market. Whether you're a seasoned investor or just starting out, our insights provide valuable information to help you make informed decisions.

size 3

Top ASX Growth Stocks for Investing

Webinars and Interviews

Chimeric Therapeutics (ASX:CHM): Solid prospects for licensing deals

  Chimeric Therapeutics (ASX:CHM) We spoke to Dr Rebecca McQualter, Chief Operating Officer of Chimeric Therapeutics…

BrainChip (ASX:BRN): Post AGM interview with CEO Sean Hehir

BrainChip (ASX:BRN) We spoke with Sean Hehir, CEO of BrainChip (ASX:BRN), after the company’s AGM to…

GreenHy2 (ASX: H2G): Interview with Managing Director Dr. Paul Dalgleish, Managing Director

GreenHy2 (ASX: H2G) We spoke to Dr. Paul Dalgleish, CEO of GreenHy2 (ASX:H2G), about the company’s…

WhiteHawk (ASX:WHK): Many opportunities in Cyber Security for the taking

WhiteHawk (ASX:WHK) We spoke with Terry Roberts, CEO of Cyber Security company WhiteHawk (ASX:WHK), about the…

The Team Behind Stocks Down Under

1rw

Stuart Roberts

Co-Founder

Stuart Roberts is the co-founder of Stocks Down Under. Previously, Stuart covered the healthcare and biotechnology sectors at NDF Research and at stockbroking firms Southern Cross Equities, Bell Potter and Baillieu Holst from 2002 to 2015, where he developed a reputation for detailed analysis on previously uncovered Life Science companies. In 2018, he co-founded Pitt Street Research

Marc-circle-300x300_webp

Marc Kennis

Co-Founder

Marc is the co-founder of Stocks Down Under and has 25+ years experience analyzing companies in a range of sectors, including Food & Beverage, Industrials, Technology, Medical Equipment, Telecom and Media. Prior to moving to Australia in 2014, he worked for a number of brokers and banks in The Netherlands, including ING and Rabobank. In 2018, Marc co-founded Pitt Street Research,

The Team Behind Stocks Down Under

STUART ROBERTS

Stuart Roberts is the co-founder of Stocks Down Under. Previously, Stuart covered the healthcare and biotechnology sectors at NDF Research and at stockbroking firms Southern Cross Equities, Bell Potter and Baillieu Holst from 2002 to 2015, where he developed a reputation for detailed analysis on previously uncovered Life Science companies. In 2018, he co-founded Pitt Street Research together with Marc.

MARC KENNIS

Marc is the co-founder of Stocks Down Under and has 20+ years experience analyzing companies in a range of sectors, including Food & Beverage, Industrials, Technology, Medical Equipment, Telecom and Media. Prior to moving to Australia in 2014, he worked for a number of brokers and banks in The Netherlands, including ING and Rabobank. In 2018, Marc co-founded Pitt Street Research, Australia's preeminent issuer-sponsored equities research firm.

PETER KILBY

Pete is Stocks Down Under's head of customer service. He is an avid investor with a knack for deep-dive company research. Pete likes the more established companies on ASX, but doesn't shy away from the occasional risky play. At Stocks Down Under he gets to do the two things he loves most, investing and talking to like-minded people.

Please enter your name.
Please enter a message.